Osteoporosıs In Chronıc Kıdney Dısease

Authors : Duygu Felek, Mustafa Asım Gedikli
Pages : 125-131
Doi:10.16919/bozoktip.1529626
View : 29 | Download : 26
Publication Date : 2025-06-15
Article Type : Research Paper
Abstract :Introduction: Bone mineral density disorders are more common in hemodialysis patients than in the general population. However, treatments to increase bone mineral density may increase vascular complications in hemodialysis patients. Bone mineral supplementation treatment regimens that do not increase hemodialysis-related cardiac mortality are necessary. Method: Thirty-three individuals (mean age 72.36±6.55 years; 20 females, 13 males) on hemodialysis for chronic kidney disease were included in the study. Body mass index, calcium, phosphorus, parathormone, bone densitometry results were recorded. In addition, the presence of intravascular calcification in the aorta on radiographs taken within the last 6 months was recorded. The relationships between these parameters were analyzed. Data were analyzed in SPSS. p< 0.05 was taken as the significance criterion. Results: When the dexa scores of 33 individuals with stage 5 CKD on hemodialysis were analyzed, the difference between T scores and PTH values was found to be significant (p=0.020*). As PTH increases, the risk of osteoporosis also increases. Osteopenia and osteoporosis were observed less in individuals with high calcium-phosphorus product. However, the difference between intravascular calcification and calcium-phosphorus product was significant (p=0.004*). The calcium-phosphorus product was significantly higher in the group with extensive aortic calcification compared to the other groups. Calcium-containing agents given with osteoporosis treatment increase cardiovascular mortality in stage-5 chronic kidney disease. Conclusion: Bone mineral density disorders should be treated in hemodialysis patients without increasing vascular calcification. In hemodialysis patients with high risk of cardiovascular disease, osteopenic follow-up can be performed by considering the benefit-harm relationship.
Keywords : Kemik Minerak Dansite Bozukluğu, Osteoporoz, Hemodiyaliz, Kardiyovasküler Mortalite

ORIGINAL ARTICLE URL